Targeted SARS-CoV-2 treatment is associated with decreased mortality in immunocompromised patients with COVID-19.

Emmanuel LafontHélène PereDavid LebeauxGeoffrey CheminetEric ThervetRomain GuillemainAdrien Flahault

Published in: The Journal of antimicrobial chemotherapy (2022)

Our results suggest that targeted COVID-19 treatment, including direct antivirals or monoclonal antibodies, is safe and efficient and could be proposed in high-risk immunocompromised patients.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
chronic kidney disease
cancer therapy
respiratory syndrome coronavirus
cardiovascular disease
risk factors
drug delivery
respiratory failure
patient reported